Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.
Robert BissonnetteJanet DuBoisPaola FacherisEster Del DucaMadeline KimJoel Correa Da RosaDamian L TrujilloSwaroop BoseAngel D PaganDavid WustrowDirk G BrockstedtBrian WongPaul D KassnerJasmina JankicevicWilliam HoLaurence E ChengEmma Guttman-YasskyPublished in: Allergy (2023)
To our knowledge, this is the first clinical study with an oral CCR4 antagonist that showed clinical improvement coupled with modulation of the cutaneous transcriptomic profile in an inflammatory skin disease.